Insider Transactions in Q4 2020 at Mirum Pharmaceuticals, Inc. (MIRM)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2020
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,167
+10.26%
|
$29,169
$7.7 P/Share
|
|
Dec 23
2020
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.23%
|
$90,000
$18.68 P/Share
|
|
Dec 23
2020
|
Ian Clements Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,470
+14.62%
|
$44,460
$18.6 P/Share
|
|
Nov 10
2020
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,371
+50.0%
|
$20,565
$15.27 P/Share
|
|
Nov 10
2020
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,371
+20.34%
|
$20,565
$15.27 P/Share
|
|
Nov 10
2020
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,275
+3.8%
|
$19,125
$15.27 P/Share
|
|
Nov 10
2020
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
822
+1.07%
|
$12,330
$15.27 P/Share
|
|
Nov 10
2020
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
861
+19.72%
|
$12,915
$15.27 P/Share
|
|
Nov 10
2020
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
595
+21.23%
|
$8,925
$15.27 P/Share
|
|
Oct 30
2020
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+44.64%
|
$175,000
$7.7 P/Share
|